Outcomes4Me builds an integrated platform that provides patients and their families with new ways to engage with healthcare systems globally. It was founded in 2017 and is based in Cambridge, Massachusetts.
Outcomes4Me's Product Videos
Outcomes4Me's Products & Differentiators
Activate patients to drive innovative drug and diagnostic uptake
Expert Collections containing Outcomes4Me
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Outcomes4Me is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Outcomes4Me has filed 1 patent.
Health informatics, Electronic health records, Telehealth, Healthcare quality, Health standards
Health informatics, Electronic health records, Telehealth, Healthcare quality, Health standards
Latest Outcomes4Me News
Sep 20, 2023
Read full article ·4 min read New relationships with Labcorp and Comcast NBCUniversal's Forecast Labs bolster Outcomes4Me's mission to democratize access to cancer care and improve health outcomes for all patients living with cancer BOSTON, Sept. 19, 2023 /PRNewswire/ -- Outcomes4Me Inc ., the developer of the first direct-to-patient, personalized and evidence-based cancer navigation platform, announced today it has entered into two innovative collaborations and investment structures, which together combine artificial intelligence (AI) technology, treatment awareness and education, diagnostic testing access and mass media to help more patients with cancer connect with the latest treatment innovation relevant to their specific diagnosis. Labcorp: Through an equity investment and collaboration agreement with Labcorp, a global leader of innovative and comprehensive laboratory services, Outcomes4Me is supercharging its efforts to improve patient outcomes by disseminating novel precision oncology treatment options through information about and access to specialty biomarker testing, including comprehensive genomic profiling, offered by Labcorp. The results of such tests can provide personalized insights to help guide a cancer patient's treatment plan. As part of this collaboration, Labcorp will also provide Outcomes4Me with marketing services, including point-of-care promotion and marketing services at select Labcorp patient service centers and locations. Forecast Labs: Outcomes4Me and Forecast Labs, a division of Comcast NBCUniversal, have entered into an earned equity investment arrangement to provide access to performance-based TV advertising to accelerate patient acquisition for Outcomes4Me. With a presence in more than 60 geographic markets and multi-device, multi-platform coverage across 170 networks, this collaboration will help ensure that every cancer patient–no matter who they are or where they receive their care–can access free resources and the clinical guidance they need to empower them to take a proactive approach to their care, based upon the latest science. Story continues "This is an important and significant time in our company history," said Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me. "Innovation is useless if it does not reach patients, and our data shows that more than a third of patients diagnosed with cancer in the United States do not have access to the latest treatments and this disparity is increasing as we move into the world of precision oncology. With more than 150,000 cancer-patient members already using our platform, I am incredibly proud that we are bringing together the power of our technology with the reach and influence of the world's largest diagnostic company and the world's largest media company to further build our community and take a major step forward in our goal to democratize healthcare and improve outcomes." "We can only deliver on the promise of precision medicine if patients have access to advanced diagnostic testing," said Maggie Rougier-Chapman, Labcorp's VP of Marketing, Pharma & Therapeutic Areas. "Through our collaboration with Outcomes4Me, we are able to expand access to guideline-driven biomarker testing options and provide personalized insights and resources that can lead to more targeted treatment plans and improved health outcomes." "Outcomes4Me is playing a vital role in an incredibly complex healthcare ecosystem by helping cancer patients to not only navigate their care but also to make science-based, informed care decisions," said Arjun Kapur, Managing Director at Forecast Labs. "More patients need to know that they too can play a more active role in managing their cancer care, and we are looking forward to helping Outcomes4Me reach the appropriate cancer patient population via TV advertising. We are excited to have Outcomes4Me as our first oncology-focused portfolio company." Outcomes4Me is the first and only direct-to-patient platform that integrates with the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and makes them patient-facing and personalized. Using AI and machine learning, Outcomes4Me gathers the FDA-approved treatment recommendations from the NCCN Guidelines®, written by and for oncologists at the world's top cancer centers, as well as clinical trials live from ClinicalTrials.gov, and translates the information into easy-to-understand, actionable guidance for patients. The Outcomes4Me app is available free to patients for download on iOS and Android . After patients download the app and answer a few questions about their health history, they can immediately gain access to personalized treatment options, genetic and genomic testing opportunities, symptom tracking and management, the latest innovation and clinical trials and health records they can understand. About Outcomes4Me Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care, gaining access to personalized, evidence-based treatment options and information. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can effectively navigate through their disease and improve their outcomes. In doing so, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, and accelerating research and access to innovation. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit www.outcomes4me.com . Cision
Outcomes4Me Frequently Asked Questions (FAQ)
When was Outcomes4Me founded?
Outcomes4Me was founded in 2017.
Where is Outcomes4Me's headquarters?
Outcomes4Me's headquarters is located at 210 Broadway, Cambridge.
What is Outcomes4Me's latest funding round?
Outcomes4Me's latest funding round is Convertible Note.
How much did Outcomes4Me raise?
Outcomes4Me raised a total of $17.2M.
Who are the investors of Outcomes4Me?
Investors of Outcomes4Me include Sierra Ventures, Asset Management Ventures, IRA Capital, Northpond Ventures and Merstal.
Who are Outcomes4Me's competitors?
Competitors of Outcomes4Me include ClinOne and 7 more.
What products does Outcomes4Me offer?
Outcomes4Me's products include Precision Marketing and 3 more.
Who are Outcomes4Me's customers?
Customers of Outcomes4Me include Invitae and Foundation Medicine.
Compare Outcomes4Me to Competitors
THREAD is a company that focuses on providing a decentralized clinical trial platform in the healthcare and life sciences industry. The company offers a platform and supporting services that enable biopharma, CROs, and life science organizations to remotely capture data from participants and sites during, in-between, and in lieu of in-clinic visits. The platform includes features such as electronic consent (eConsent), electronic clinical outcome assessment (eCOA), sensors, reminders, and telehealth virtual visits. It was founded in 2005 and is based in Tustin, California.
Akkure is a company that focuses on integrating Artificial Intelligence (AI) and Genomics in the field of cancer trial recruitment, operating within the healthcare and technology sectors. The company offers a digital platform that uses AI to match patients' data with relevant clinical trials, aiming to boost enrollment and increase the chances of successful trials. Additionally, it provides solutions for charities, pharmacies, hospitals, and primary care centers, facilitating precise patient searches for suitable cancer trials and streamlining clinical trial recruitment. Akkure was formerly known as Akkure Genomics. It was founded in 2019 and is based in Dublin, Ireland.
Ancora is a search tool that allows patients to look for relevant clinical trials in an easily searchable, personally tailored way. It saves personalized trial searches and results, sets automatic updates, connects to trials, tracks progress toward enrollment, and more. It was founded in 2017 and is based in Zurich, Switzerland.
Trialbee is a company that focuses on enrollment performance in the clinical research sector. The company offers a patient matching and analytics-driven enrollment platform that simplifies the patient recruitment process for clinical trials, reducing risk and improving efficiency. It primarily serves the clinical research industry. It was founded in 2010 and is based in Malmo, Sweden.
Mika Health accompanies patients through therapy with a specially developed support program. The company supports cancer patients coping with mental and medical challenges. It was founded in 2017 and is based in Berlin, Germany
Tempus is a company focused on precision medicine, operating within the healthcare and artificial intelligence sectors. The company offers services that utilize artificial intelligence to provide physicians with real-time, data-driven decisions for personalized patient care and targeted therapies. It also facilitates the discovery, development, and delivery of optimized therapeutic options for patients. It was founded in 2015 and is based in Chicago, Illinois.